Dr. Carlos Bosques

Dr. Carlos Bosques

Senior Vice President of Research

Decoding the cellular and molecular communications between the immune and nervous systems is paramount to effectively intervene with the pathophysiological pathways at the core of food allergies. FASI investigators are paving the way to develop a new and unique level of understanding of these mechanisms. I am honored to have the opportunity to work with this innovative and passionate team in decoding these complex systems and, more importantly, to embark on the translation of these groundbreaking discoveries into alternatives to more effectively diagnose and treat food allergies. Working with the best scientists in our own unconventional approach, I believe we are uniquely positioned to create new alternatives to improve the quality of life for millions of people living with food allergies across the world.

As Senior Vice President of Research, Dr. Carlos Bosques is responsible for leveraging the interface of Immunology, Neuroscience, Gastroenterology and Microbiology to discover and develop therapeutic alternatives for treating food allergies.

Carlos has dedicated more than 16 years to the development of biomedical technology platforms and novel therapeutics. As a passionate drug developer, he is proficient in identifying therapeutic business opportunities and developing therapeutics from discovery to the clinical stage.

Prior to FASI, Carlos held different leadership positions in the biotechnology and pharmaceutical industries. For example, Carlos played a leading role in developing the biotherapeutic infrastructure and pipeline at Momenta Pharmaceuticals (now Johnson & Johnson). Heading Drug Discovery and Translational Research Departments, Dr. Bosques was responsible for leading the discovery and early development of novel immuno-therapeutics for the treatment of autoimmune and inflammatory diseases. Carlos’ leadership experience also extends to medical devices and consumer goods. For example, as Head of Research & Innovation at Evolved by Nature, he led the development of novel peptide libraries and their applications across therapeutics, medical devices and consumer goods business areas.